Arvinas, Inc. (NASDAQ:ARVN – Get Free Report) was the target of a large drop in short interest in the month of September. As of September 30th, there was short interest totalling 10,670,000 shares, a drop of 16.4% from the September 15th total of 12,760,000 shares. Based on an average daily volume of 647,700 shares, the days-to-cover ratio is presently 16.5 days.
Arvinas Price Performance
NASDAQ ARVN opened at $25.90 on Wednesday. The business’s fifty day moving average is $25.12 and its 200-day moving average is $28.64. The stock has a market capitalization of $1.77 billion, a price-to-earnings ratio of -4.37 and a beta of 1.97. Arvinas has a one year low of $13.57 and a one year high of $53.08.
Arvinas (NASDAQ:ARVN – Get Free Report) last announced its quarterly earnings data on Tuesday, July 30th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($1.08) by $0.59. The company had revenue of $76.50 million during the quarter, compared to the consensus estimate of $33.27 million. During the same period in the prior year, the firm posted ($1.25) EPS. The business’s revenue was up 40.4% on a year-over-year basis. Research analysts expect that Arvinas will post -3.51 EPS for the current fiscal year.
Hedge Funds Weigh In On Arvinas
Wall Street Analyst Weigh In
ARVN has been the topic of several research reports. Wedbush restated an “outperform” rating and set a $57.00 price objective on shares of Arvinas in a report on Tuesday, July 30th. HC Wainwright reaffirmed a “buy” rating and issued a $87.00 price target on shares of Arvinas in a research report on Thursday, August 1st. Cantor Fitzgerald reissued an “overweight” rating on shares of Arvinas in a report on Monday, September 9th. Oppenheimer dropped their target price on Arvinas from $70.00 to $50.00 and set an “outperform” rating on the stock in a report on Wednesday, July 31st. Finally, Barclays cut their target price on Arvinas from $60.00 to $48.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 31st. Two research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $57.50.
View Our Latest Stock Analysis on ARVN
About Arvinas
Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.
Featured Articles
- Five stocks we like better than Arvinas
- What is a Secondary Public Offering? What Investors Need to Know
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- AMD Gains Momentum With AI: Can It Beat Expectations?
- Market Cap Calculator: How to Calculate Market Cap
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.